Canadian guidelines for the management of acute exacerbations of chronic bronchitis

Canadian Respiratory Journal

Volumn 10, Issue SUPPL. B, 2003, Pages

  Balter, Meyer S ^a   La Forge, Jacques ^b   Low, Donald E ^a,c   Mandell, Lionel ^d   Grossman, Ronald F ^a   Anzueto, Antonio ^e   Born, Abraham ^a   Bouchard, Jacques ^f   Duguid, Nigel J D ^g   Harding, Godfrey ^h   Julien, Marcel ⁱ   Lampron, Noel ^b   Levy, Robert D ^j   McSherry, James A ^k   Weiss, Karl A ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^f ST JOSEPH S HOSPITAL   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

more..

Author keywords

Antibiotics; Chronic bronchitis; Exacerbatiosn; Risk stratification

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; BUDESONIDE; CEFTRIAXONE; CHLORAMPHENICOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; IPRATROPIUM BROMIDE; LEVOFLOXACIN; METHYLPREDNISOLONE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; OFLOXACIN; OXYGEN; OXYTETRACYCLINE; PENICILLIN G; PREDNISONE; SALBUTAMOL; TETRACYCLINE; UNINDEXED DRUG;

AIR POLLUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; BREATHING EXERCISE; CANADA; CELL INFILTRATION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HIGH RISK POPULATION; HUMAN; HYPERCAPNIA; HYPERGLYCEMIA; HYPOXEMIA; MORBIDITY; MORTALITY; NEUTROPHIL; NONHUMAN; OCCUPATIONAL EXPOSURE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; T LYMPHOCYTE; TREATMENT FAILURE;

EID: 0141670266     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/486285     Document Type: Review

References (372)

1. Balter M, Hyland R, Low D. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J 1994;151 (Suppl):7-33.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31:383-421.
3. Canadian Lung Association. Lung Facts 1991;3.
4. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-1420.
5. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
6. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965;1:775-9.
7. Oswald NC, Harold JT, Martin WJ. Clinical pattern of chronic bronchitis. Lancet 1953;265:639-643.
8. Manfreda J, Mao Y, Litven W, Morbidity and mortality from chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S19-26.
9. Lacasse Y, Brooks D, Goldstein RS. Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. Chest 1999;116:306-13.
10. Enright PL, Kronmal RA, Higgins MW, Schenker MB, Haponik EF. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994;106:827-34.
11. US Bureau of the Census. Statistical Abstract of the United States. (14th edn). Washington, DC, US Bureau of the Census, 1994/1995.
12. Woolcock AJ. Epidemiology of chronic airways disease. Chest 1989;96(Suppl 3):302S-6S.
13. Lange P, Groth S, Nyboe J, et al. Chronic obstructive lung disease in Copenhagen: Cross-sectional epidemiological aspects. J Intern Med 1989;226:25-32.
14. Bakke P, Baste V, Hanoa R, Gulsvik A. Prevalence of obstructive lung disease in a general population: Relation to occupational title and exposure to some airborne agent. Thorax 1991;46:863-70.
15. Brotons B, Perez J, Sanchez-Toril F, et al. Prevalencia de la enfermedad obstructiva cronica y el asma: estudio transversal. Arch Bronconeumol 1994;30:149-52.
16. Lundback B, Nystrom L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: Respiratory symptoms assessed in a postal survey. Eur Respir J 1991;4:257-66.
17. Ball P, Make B. Acute exacerbations of chronic bronchitis: An international comparison. Chest 1998;113(Suppl):199S-204S.
18. Pandey MR. Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 1984;39:337-9.
19. Higgins M, Thom T. Incidence, prevalence, and mortality: Intra-and inter-county differences. In: Hensley M, Saunders N, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker, 1990:23-43.
20. U.S. Surgeon General. The Health Consequences of Smoking: Chronic obstructive lung disease. (DHHS Publication No. 84-50205). 1994. Washington, DC, U.S. Deparment of Health and Human Services.
21. Sherrill DL, Lebowitz MD, Burrows B. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 1990;11:375-87.
22. Buist A. Risk factors for COPD. Eur Resp Rev 1996;6:253-8.
23. Becklake MR. Chronic air flow limitation: Its relationship to work in dusty occupations. Chest 1985;88:608-17.
24. Oxman AD, Muir DC, Shannon HS, Stock SR, Hnizdo E, Lange HJ. Occupational dust exposure and chronic obstructive pulmonary disease: A systematic overview of the evidence. Am Rev Respir Dis 1993;148:38-48.
25. Seersholm N, Kok-Jensen A. Clinical features and prognosis of lifetime non-smokers with severe alpha 1 antirypsin deficiency. Thorax 1998;53:265-8.
26. Cohen BH, Ball WC Jr, Bias WB, et al. A genetic-epidemiologic study of chronic obstructive pulmonary disease. I. Study design and preliminary observations. Johns Hopkins Med J 1975;137:95-404.
27. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996;153:1802-11.
28. Postma D, De Vries K, Koeter G, Sluiter H. Independent influence of reversiblity of air-flow obstruction on nonspecific hyperreactivity on the long term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986;134:276-80.
29. Fielding JE, Phenow KJ. Health effects of involuntary smoking. N Engl J Med 1988;319:1452-60.
30. Leuenberger P, Schwartz J, Ackermann-Liebrich U, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 1994;150:1222-8.
31. Gold D, Tager I, Weiss S, Tosteson T, Speizer F. Acute lower respiratory illness in childhood as a predictor of lung function and chronic respiratory symptoms. Am Rev Respir Dis 1989;140:877-84.
32. Shaheen S, Barker D, Shiell A, Crocker F, Wield G, Holgate S. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994;149:616-9.
33. Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jefferies WA, Hogg JC. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 1992;146:177-84.
34. Cole P, Wilson R. Host-microbial interrelationships in respiratory infection. Chest 1989;95:217S-21S.
35. Pope CA III, Schwartz J, Ransom MR. Daily mortality and PM10 pollution in Utah Valley. Arch Environ Health 1992;47:211-7.
36. Zemp E, Elsasser S, Schindler C, et al. Long term ambient air pollution and respiratory symptoms in adults (SAPALDIA Study). Am J Crit Care Med 1999;159:1257-66.
37. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 1996;109:115-9.
38. Prescott E, Bjerg A, Anderson P, Lange P, Vestbo J. Gender differences in smoking effects on lung function and risk of hospitalization for COPD: Results from a Danish longitudinal population study. Eur Respir J 1997;10:822-7.
39. Leynaert B, Bousquet J, Henry C, et al. Is bronchial hyperresponsiveness more frequent in women then in men. Am J Respir Crit Care Med 1997;156:1413-20.
40. Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000;21:67-86.
41. Jeffery PK. Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Exp Allergy 1999;29(Suppl 2):14-26.
42. Reid L. Measurement of the bronchial mucous gland layer: A diagnostic yardstick in chronic bronchitis. Thorax 1960;15:132-41.
43. Jamal K, Cooney TP, Fleetham JA, Thurlbeck WM. Chronic bronchitis. Correlation of morphologic findings to sputum production and flow rates. Am Rev Respir Dis 1984;129:719-22.
44. Haraguchi M, Shimura S, Shirato K. Morphologic analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. Am J Respir Crit Care Med 1999;159:1005-13.
45. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br Med J (Clin Res Ed) 1985;291:1235-9.
46. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
47. Fletcher C, Peto R. The natural history of chronic air flow obstruction. BMJ 1977;1:1645-8.
48. Fletcher C. The Natural History of Chronic Bronchitis and Emphysema: An 8-year Study of Working Men in London. New York: Oxford University Press, 1976.
49. Kauffmann F, Drouet D, Lellouch J, Brille D. Twelve years spirometric changes among Paris area workers. Int J Epidemiol 1979;8:201-12.
50. Higgins MW, Keller JB, Becker M, et al. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982;125:144-51.
51. Kanner R, Renzetti A Jr, Klauber M, Smith C, Golden C. Variables associated with changes in spirometry in patients with obstructive lung diseases. Am J Med 1979;67:44-50.
52. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-5.
53. Sherman CB, Xu X, Speizer FE, Ferris BG Jr, Weiss ST, Dockery DW. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992;146:855-9.
54. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990;45:579-85.
55. Dowson L, Guest F, Stockley R. Longitudinal changes in physiological, radiological, and health status measurements in alpha-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001;164:1805-9.
56. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64.
57. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974;291:755-8.
58. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978;298:1277-81.
59. Tager IB, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988;138:837-49.
60. McClosky SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ, Lomas DA. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of air flow obstruction. Crit Care Med 2001;164:1419-24.
61. Silverman EK. Genetics of chronic obstructive pulmonary disease. Novartis Foundation Symposium 2001;234:45-58.
62. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
63. Richman-Eisenstat JB, Jorens PG, Hebert CA, Ueki I, Nadel JA. Interleukin-8: An important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993;264:L413-8.
64. Riise GC, Ahlstedt S, Larsson S, et al. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax 1995;50:360-5.
65. Pesci A, Balbi B, Majori M, et al. Inflammatory cells in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998;12:380-6.
66. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95.
67. 1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71.
68. Martin TR, Raghu G, Maunder RJ, Springmeyer SC. The effects of chronic bronchitis and chronic air-flow obstruction on lung cell populations recovered by bronchoalveolar lavage. Am Rev Respir Dis 1985;132:254-60.
69. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
70. Fournier M, Lebargy F, Le Roy LF, Lenormand E, Pariente R. Intraepithelial T-lymphocyte subsets in the airways of normal subjects and of patients with chronic bronchitis. Am Rev Respir Dis 1989;140:737-42.
71. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-6.
72. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537-48.
73. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996;26:766-74.
74. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-50.
75. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: The role of leukotriene B4. Eur Respir J 2000;15:274-80.
76. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
77. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557-65.
78. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-55.
79. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
80. Haas H, Morris J, Samson S, Kilbourn J, Kim P. Bacterial flora of the respiratory tract in chronic bronchitis: Comparison of transtracheal, fiberbronchoscopic, and oropharyngeal sampling methods. Am Rev Respir Dis 1977;116:41-7.
81. Hager H, Verghese A, Alvarez S, Berk S. Branhamella catarrhalis respiratory infections. Rev Infect Dis 1987;9:1140-9.
82. Tager I, Speizer F. Role of infection in chronic bronchitis. N Engl J Med 1975;292:563-71.
83. Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 1984;45:197-202.
84. Adler K, Hendley D, Davis G. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol 1986;125:501-14.
85. Wilson R, Pitt T, Taylor G, et al. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest 1987;79:221-9.
86. Wilson R, Cole P. The effect of bacterial products on ciliary function. Am Rev Respir Dis 1988;138:S49-S53.
87. Read R, Wilson R, Rutman A, et al. Interaction of nontypable Haemophilus influenzae with human respiratory mucosa in vitro. J Infect Dis 1991;163:549-58.
88. Wilson R, Tilotson G, Ball P. Clinical studies in chronic bronchitis: A need for better definition and classification of severity. J Antimicrob Chemother 1996;37:205-208.
89. Cosio M, Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 1999;160(Suppl):S21-5.
90. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
91. Bresser P, Out T, Van Alphen L, Jansen H, Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection: Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:947-52.
92. Huang S-L, Su C-H, Chang S-C. Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997;156:1436-9.
93. Murphy T, Sethi S. Bacterial infection in chronic obstructive pulonary disease. Am Respir Dis 1992;146:1067-83.
94. Murphy T, Apicella M. Nontypable Haemophilus influenzae: A review of clinical aspects, surface antigens, and the human immune response to infection. Rev Infect Dis 1987;9:1-15.
95. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: A bronchoscopic study. Eur Respir J 1997;10:1137-44.
96. Mitchell J, Hill S. Immune response to Haemophilus influenzae in patients with chronic obstructive lung disease. Clin Diagnos Lab Immunol 2000;7:25-30.
97. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999;13:343-8.
98. Monso E, Rosell A, Bonet G, et al. Risk factors of lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999;13:338-42.
99. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
100. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-6.
101. Van Schilfgaarde M, Eijk P, Regelink A, et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. Microb Pathog 1999;26:249-62.
102. Bandi V, Apicella M, Moson E, et al. Non-typeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Respir Crit Care Med 2001;164:2114-9.
103. Moller L, Timens W, Van Der Bij W, et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 1998;157:950-6.
104. Groenveld K, Van Alphen L, Eijk P, Jansen H, Zanen H. Changes in outer membrane proteins of nontypable Haemophilus influenzae in patients with chronic obstructive pulmonary disease. J Infect Dis 1988;158:360-5.
105. Groeneveld K, Van Alphen L, Voorter C, Eijk P, Jansen H, Zanen H. Antigenic drift of Haemophilus influenzae in patients with chronic obstructive pulmonary disease. Infect Immun 1989;57:3038-44.
106. Fogarty CM, Bettis RB, Griffin TJ, Keyserling CH, Nemeth MA, Tack KJ. Comparison of a 5 day regimen of cefdinar with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:851-8.
107. Wilson R, Kubin I, Deppermann K-M, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
108. Shah PM, Maesen FPV, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: Results of a randomized, double-blind study. J Antimicrob Chemother 1999;43:529-39.
109. Langan C, Zuck P, Vogel F, et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:515-23.
110. Georgopoulos A, Borek M, Ridl W, for the Amoxycillin Bronchitis Study Group. Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2001;47:67-76.
111. Habib M, Gentry L, Rodriguez-Gomez G, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 1998;7:101-9.
112. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998;42:114-20.
113. DeAbate C, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir Care 1997;42:206-23.
114. Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976;113:465-74.
115. McHardy V, Inglis J, Calder M, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980;74:228-38.
116. Fagon J, Chastre J, Trouillet J, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990;142:1004-8.
117. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
118. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1498-1505.
119. Pela R, Marchesani F, Agostinelli C, et at. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: A bronchoscopic investigation. Monaldi Arch Chest Dis 1998;53:262-7.
120. Anthonisen NR, Manfreda J, Warren CF, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
121. Sachs A, Koeter G, Groenier K, Van Der Waaij D, Schiphuis J, Meyboom-de Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758-63.
122. Stockley R, O'Brien C, Pye A, Hill S. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
123. Stockley R, Bayley D, Hill S, Hill A, Crooks S, Campbell E. Assessment of airway neutrophils by sputum colour: Correlation with airways inflammation. Thorax 2001;56:366-72.
124. Gompertz S, Baley D, Hill S, Stockley R. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
125. Von Hertzen L, Alakarppa H, Koskinen R, et al. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997;118:155-64.
126. Buscho R, Saxtan D, Shultz P, Finch E, Mufson M. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978;137:377-83.
127. Smith C, Kanner R, Golden C, Klauber M, Renzetti AJ. Effect of viral infection on pulmonary function in patients with chronic obstructive pulmonary disease. J Infect Dis 1980;141:271-80.
128. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23.
129. Blasi F, Legnani D, Lombardo V, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993;6:19-22.
130. Beaty C, Grayston J, Wang S-P, Kuo C-C, Reto C, Martin T Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;144:1408-10.
131. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999;160:349-53.
132. Smith C, Golden C, Klauber M, et al. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 1976;134:552-61.
133. Stenhouse A. Rhinovirus infection in acute exacerbation of chronic bronchitis: A controlled prospective study. BMJ 1976;3:461-3.
134. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
135. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
136. Mushlin AI, Black ER, Connolly CA, Buonaccorso KM, Eberly SW. The necessary length of hospital stay for chronic pulmonary disease. JAMA 1991;266:80-3.
137. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67.
138. Burk RH, George RB. Acute respiratory failure in chronic obstructive pulmonary disease. Immediate and long-term prognosis. Arch Intern Med 1973;132:865-8.
139. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7.
140. Cydulka RK, McFadden ER Jr, Emerman CL, Sivinski LD, Pisanelli W, Rimm AA. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1997;156:1807-12.
141. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67-71.
142. Peach H, Pathy MS. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax 1981;36:585-9.
143. Hagedorn SD. Acute exacerbations of COPD. How to evaluate severity and treat the underlying cause. Postgrad Med 1992;91:105-7.
144. Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993;22:680-4.
145. Tsai TW, Gallagher EJ, Lombardi G, Gennis P, Carter W. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993;22:1854-8.
146. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med 1989;149:2493-6.
147. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989;96:1247-51.
148. Peto R, Speizer F, Cochrane A, et al. The relevance in adults of air-flow obstruction but not of mucus hypersecretion, to morality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983;128:491-500.
149. Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Clin Chest Med 1990;11:555-69.
150. Vitacca M, Clini E, Porta R, Foglio K, Ambrosino N. Acute exacerbations in patients with COPD: Predictors of need for mechanical ventilation. Eur Respir J 1996;9:1487-93.
151. 1 to clinical outcomes during exacerbations of chronic obstuctive pulmonary disease. The Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000;161:1201-5.
152. Mannino DM, Etzel RA, Flanders WD. Do the medical history and physical examination predict low lung function? Arch Intern Med 1993;153:1892-7.
153. Kesten S, Chapman K. Physician perceptions and management of COPD. Chest 1993;104:254-8.
154. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax 1996;51:164-8.
155. Kuhl DA, Agiri OA, Mauro LS. Beta-agonists in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Pharmacother 1994;28:1379-88.
156. Emerman CL, Cydulka RK. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997;29:474-8.
157. O'Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute air flow obstruction. Lancet 1989;1(8652):1418-20.
158. Backman R, Helstrom P. Fenoterol and ipratropium bromide for treatment of patients with chronic bronchitis. Curr Ther Res 1985;38:135-40.
159. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835-9.
160. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987;82:59-64.
161. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50:834-7.
162. Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990;98:295-7.
163. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995;25:470-3.
164. Shrestha M, O'Brien T, Haddox R, Gourlay HS, Reed G. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Ann Emerg Med 1991;20:1206-9.
165. Turner M, Patel A, Ginsburg S, FitzGerald J. Bronchodilator delivery in acute air flow obstruction. A meta-analysis. Arch Intern Med 1997;157:1736-44.
166. Rice KL, Leatherman JW, Duane PO, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 1987;107:305-9.
167. Seidenfeld JJ, Jones WN, Moss RE, Tremper J. Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1984;13:248-52.
168. Schmidt GA, Hall JB. Acute or chronic respiratory failure. Assessment and management of patients with COPD in the emergency setting. JAMA 1989;261:3444-53.
169. Bone R, Pierce A, Johnson RJ. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: A reappraisal. Am J Med 1978;65:896-902.
170. Rosen RL. Acute respiratory failure and chronic obstructive lung disease. Med Clin North Am 1986;70:895-907.
171. Derenne JP, Fleury B, Pariente R. Acute respiratory failure of chronic obstructive pulmonary disease. Am Rev Repir Dis 1988;138:1006-33.
172. Weinberger SE, Schwartzstein RM, Weiss JW. Hypercapnia. N Engl J Med 1989;321:1223-31.
173. Stradling JR. Hypercapnia during oxygen therapy in airways obstruction: A reappraisal. Thorax 1986;41:897-902.
174. Levi-Valensi P, Weitzenblum E, Pedinielli JL, Racineux JL, Duwoos H. Three-month follow-up of arterial blood gas determinations in candidates for long-term oxygen therapy. A multicentric study. Am Rev Respir Dis 1986;133:547-51.
175. Anonymous. Recommendations for long term oxygen therapy (LTOT), European society of Pneumology Task Group. Eur Respir J 1992;2:160-4.
176. Timms RM, Kvale PA, Anthonisen NR, et al. Selection of patients with chronic obstructive pulmonary disease for long-term oxygen therapy. JAMA 1981;245:2514-5.
177. Finiguerra M, Conti P, Figura I, Legnani W, Morandini G. Clinical study on an antibiotic and mucolytic association (amoxicillin and domiodal) in hypersecretory chronic bronchopulmonary diseases. Current Ther Res 1982;31:895-905.
178. Langlands JH. Double-blind clinical trial of bromhexine as a mucolytic drug in chronic bronchitis. Lancet 1970;1(7644):448-50.
179. Aylward M. A between-patient, double-blind comparison of S-carboxymethylcysteine and bromhexine in chronic obstructive bronchitis. Curr Med Res Opin 1973;1:219-27.
180. Anthonisen P, Riis P, Sogaard-Anderson T. The value of lung physiotheraphy in the treatment of acute exacerbations in chronic bronchitis. Acta Med Scand 1964;175:715-9.
181. Newton DA, Bevans HG. Physiotherapy and intermittent positive-pressure ventilation of chronic bronchitis. BMJ 1978;2:1525-8.
182. 1 in chronic bronchitis. Med J Aust 1975;1:33-5.
183. Connors AF, Hammon WE, Martin RJ, Rogers RM. Chest physical therapy. The immediate effect on oxygenation in acutely ill patients. Chest 1980;78:559-64.
184. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial. Lancet 2000;355:1931-5.
185. Keenan SP, Kernerman PD, Cook DJ, Martin CM, McCormack D, Sibbald WJ. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: A meta-analysis. Crit Care Med 1997;25:1685-92.
186. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001;163:540-77.
187. Anton A, Guell R, Gomex J, et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic air flow limitation. Chest 2000;117:828-33.
188. Ambrosino N, Foglio K, Rubini F, Clini E, Nava S, Vitacca M. Non-invasive mechanical ventilation in acute respiratory failure due to chronic obstructive pulmonary disease: Correlates for success. Thorax 1995;50:755-7.
189. Meduri G, Turner R, Abou-Shala N, Wunderink R, Tolley E. Noninvasive positive pressure ventilation via face mask. First-line intervention in patients with hypercapnic and hypoxemic respiratory failure. Chest 1996;109:179-93.
190. Emerman C, Connors A, Lukens T, May M, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989;95:563-7.
191. Thompson W, Nielson C, Carvalho P, Charan N, Crowley J. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
192. Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet 1999;354:456-60.
193. Niewoehner D, Erbland M, Deupree R, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7.
194. Murata G, Gorby M, Chick T, Halperin A. Intravenous and oral corticosteroids for the prevention of relapse after treatment for decompensated COPD: Effect on patients with a history of multiple relapses. Chest 1990;98:845-9.
195. Abbinante-Nissen J, Simpson L, Leikauf G. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1995;268:L601-6.
196. Llewellyn-Jones C, Harris T, Stockley R. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Resp Crit Care Med 1996;153:616-21.
197. Tomee J, Koeter G, Hiemstra P, Kauffman H. Secretory leukoprotease inhibitor: A native antimicrobial protein presenting a new therapeutic option? Thorax 1998;53:114-6.
198. Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucorticoids in severe exacerbations of COPD. Chest 2001;119:726-30.
199. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD. Eur Respir J 1997;10:417-23.
200. Woolhouse C, Hill S, Stockley R. Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. Thorax 2001;56:947-53.
201. Maltais F, Ostinelli J, Bourbeau J, Tonnel A, Jacquemet N, Haddon J. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703.
202. Elmes P, Fletcher C, Dutton A. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. Br Med J 1957;2:1272-5.
203. Berry D, Fry J, Hindley C, et al. Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet 1960;1:137-9.
204. Elmes P, King T, Langlands J, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 1965;5467:904-8.
205. Peterson E, Esmann V, Honcke P, Munkner C. A controlled study of the effect of treatment on chronic bronchitis: an evaluation using pulmonary function tests. Acta Med Scand 1967;182:293-305.
206. Pines A, Raafat H, Greenfield J, Linsell W, Solari M. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 1972;66:107-15.
207. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 1982;97:18-21.
208. Allegra L, Grasi E, Pozzi E. Pruolo degli antibiotici nel trattamento delle riacutizza della bronchite cronica. Ital J Chest Dis 1991;45:138-48.
209. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomized placebo-controlled trial. Lancet 2001;358:2020-35.
210. Sethi S, Paluri R, Grant E, Murphy T. Prediction models for the etiology of acute exacerbations of COPD. Am J Resp Crit Care Med 1999;159:A819. (Abst)
211. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
212. Ball P, Harris J, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 1995;88:61-8.
213. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993;341:511-4.
214. Destache CJ, Dewan N, O'Donohue WJ, Campbell JC, Angelillo VA. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;43(Suppl A):107-13.
215. Doern GV, Brueggemann AB, Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997;41:292-7.
216. Doern G, Pfaller M, Kugler K, Freeman J, Jones R. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998;27:764-70.
217. Sportel JH, Koeter GH, van Altena R, Lowenberg A, Boersma WG. Relation between beta-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease (COPD). Thorax 1995;50:249-53.
218. Doern GV, Brueggemann A, Holley HP, Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-13.
219. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997;29:249-57.
220. Moellering R. Meeting the challenges of beta-lactamases. J Antimicrob Chemother 1993;31(Suppl A):1-8.
221. National committee for clinical laboratory standards. Performance standards for antimicrobial susceptibility. Ninth information supplement. Wayne, PA, 1999.
222. Forward K. The epidemiology of penicillin resistance in Streptococcus pneumoniae. Semin Respir Infect 1999;14:243-54.
223. Zhanel G, Karlowsky J, Palatnick L, Vercaigne L, Low D, Hoban D. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob Agents Chemother 1999;43:2504-9.
224. Thornsberry C, Ogilvie P, Holley HJ, Sahm D. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study. Antimicrob Agents Chemother 1999;43:2612-23.
225. Jacobs M, Bajaksouzian S, Zilles A, Lin G, Pankuch G, Appelbaum P. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother 1999;43:1901-8.
226. Marton A, Meszner Z. Epidemiological studies on drug resistance in Streptococcus pneumoniae in Hungary: An update for the 1990s. Microb Drug Resist 1999;5:201-5.
227. Fluit A, Schmitz F, Jones M, Acar J, Gupta R, Verhoef J. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: First results from the SENTRY antimicrobial surveillance program 1997. SENTRY participants group. Int J Infect Dis 1999;3:153-6.
228. Song J, Lee N, Ichiyama S, et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis 1999;28:1206-11.
229. Campbell GJ, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998;26:1188-95.
230. Klugman K, Feldman C. Penicillin and cephalosporin-resistant streptococcus pneumonia: Emerging treatment for an emerging problem. Drugs 1999;58:1-4.
231. Dowell S, Butler J, Giebink G, et al. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
232. Butler J, Dowell S, Breiman R. Epidemiology of emerging pneumococcal drug resistance: Implications for treatment and prevention. Vaccine 1998;16:1693-7.
233. National committee for clinical laboratory standards. Performance Standards for Antimicrobial Susceptibility Testing. Twelfth informational supplement. M100-S12. 2002. Wayne, PA, 2002.
234. Davidson R. A cross Canada surveillance of antimicrobial resistance in respiratory tract pathogens. Can J Infect Dis 1999;10:128-33.
235. Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis 1992;14:1119-23.
236. Wallace RJ Jr, Nash DR, Steingrube VA. Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrhalis. Am J Med 1990;88(Suppl 5A):46S-50S.
237. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander project 1992-1996. Chemother 1999;11(Suppl 1):5-21.
238. Richter S, Brueggemann A, Huynh H, et al. A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. Int J Antimicrob Agents 1999;13:99-107.
239. Doern G, Jones R, Pfaller M, Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999;43:385-9.
240. Low DE. Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience. Microb Drug Resist 1995;1:223-34.
241. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996;40:2562-6.
242. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40:1817-24.
243. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-99.
244. Johnston NJ, De Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425-6.
245. Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999;29:1186-8.
246. Nishijima T, Saito Y, Aoki A, Toriya M, Toyonaga Y, Fujii R. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics. J Antimicrob Chemother 1999;43:637-43.
247. Eady EA, Ross JI, Tipper JL, Walters CE, Cove JH, Noble WC. Distribution of genes encoding erythromycin ribosomal methylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. J Antimicrob Chemother 1993;31:211-7.
248. Leclercq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991;35:1273-6.
249. Ross JI, Farrell AM, Eady EA, Cove JH, Cunliffe WJ. Characterisation and molecular cloning of the novel macrolid-estreptogramin B resistance determinant from Staphylococcus epidermidis. J Antimicrob Chem 1989;24:851-62.
250. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-1.
251. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis 1999;5:757-65.
252. Amsden GW. Pneumococcal macrolide resistance - Myth or reality? J Antimicrob Chemother 1999;44:1-6.
253. Lynch JI, Martinez F. Clinical relevance of macrolide-resistant streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002;34:S27-S46.
254. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-9.
255. Varon E, Janoir C, Kitzis MD, Gutmann L. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:302-6.
256. Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones. Mol Microbiol 1994;13:641-53.
257. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996;40:2760-4.
258. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996;40:2252-7.
259. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:2321-6.
260. Aeschlimann JR, Kaatz OW, Rybak MJ. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. J Antimicrob Chemother 1999;44:343-9.
261. Chen D, McGeer A, de Azavedo J, Low D. The Canadian bacterial surveillance network. Decreased susceptibility of streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
262. Vila J, Ruiz J, Sanchez F, et al. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob Agents Chemother 1999;43:161-2.
263. Campos J, Roman F, Georgiou M, et al. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis 1996;174:1345-7.
264. Cunliffe NA, Emmanuel FX, Thomson CJ. Lower respiratory tract infection due to ciprofloxacin resistant Moraxella catarrhalis. J Antimicrob Chemother 1995;36:273-4.
265. DiPersio J, Jones R, Barrett T, Doern G, Pfaller M. Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program (1998). Diagn Microbiol Infect Dis 1998;32:131-5.
266. Bootsma HJ, Troelstra A, Veen-Rutgers A, Mooi FR, de Neeling AJ, Overbeek BP. Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands. J Antimicrob Chemother 1997;39:292-3.
267. Cooper B, Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989;87:475.
268. Davies BI, Maesen FP, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur Clin Microbiol 1986;5:226-31.
269. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520-1.
270. Thys JP. Quinolones in the treatment of bronchopulmonary infections. Rev Infect Dis 1988;10(Suppl 1):5212-7.
271. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999;44:835-8.
272. Birmingham MC, Guarino R, Heller A, et al. Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. J Antimicrob Chemother 1999;43(Suppl A):43-8.
273. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7.
274. Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1999;43:1118-23.
275. Linares J, De La Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:1546-7.
276. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-22.
277. de Groot R, Sluijter M, de Bruyn A, et al. Genetic characterization of trimethoprim resistance in Haemophilus influenzae. Antimicrob Agents Chemother 1996;40:2131-6.
278. Maskell JP, Sefton AM, Hall LM. Mechanism of sulfonamide resistance in clinical isolates of Streptococcus pnuemoniae. Antimicrob Agents Chemother 1997;41:2121-6.
279. Adrian P, Klugman K. Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:2406-13.
280. Dale G, Broger C, D'Arcy A, et al. A single amino acid substitution in Staphylococcus aureus dihyrofolate reductase determines trimethoprim resistance. J Mol Biol 1997;266:23-30.
281. Widdowson C, Klugman K. Molecular mechanisms of resistance to commonly used non-betalactam drugs in Streptococcus pneumoniae. Semin Respir Infect 1999;14:255-68.
282. Speer B, Shoemaker N, Salyers A. Bacterial resistance to tetracycline: Mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992;5:387-99.
283. Widdowson C, Klugman K. The molecular mechanisms of tetracycline resistance in the pneumococcus. Microb Drug Resist 1998;4:79-84.
284. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: Factors associated with poor treatment outcome. Chest 2000;117:662-71.
285. Miravitlles M, Murio C, Guerrero T, on behalf of the DAFNE study group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:928-33.
286. Adams S, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-52.
287. Grossman R, Mukherjee J, Vaughan D, et al, for the Canadian Ciprofloxacin Health Economic Study Group. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998;113:131-41.
288. Kessler R, Faller M, Fourgaut G, Nennevier B, Weitsenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Crit Care Med 1999;159:158-64.
289. Garcia-Aymerich J, Monso E, Marrales R, et al. Risk factors for a chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2001;164:1002-7.
290. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: A multiple logistic regression analysis. The EOLO Study Group. Respiration 2000;67:495-501.
291. Antonelli-Incalzi A, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-800.
292. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999;21:576-91.
293. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55.
294. Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults. Br Med J 1998;316:906-10.
295. Smucny J, Becker L, Glazier R, McIsaac W. Are antibiotics effective treatment for acute bronchitis? A meta-analysis. J Fam Pract 1998;47:453-60.
296. Bent S, Saint S, Vittinghoff E, Grady D. Antibiotics in acute bronchitis: A meta-analysis. Am J Med 1999;107:62-7.
297. Gonzales R, Sande M. Uncomplicated acute bronchities. Ann Intern Med 2000;133:981-91.
298. Macfarlane J, Holmes W, Gard P, Thornhill D, Macfarlane R, Hubbard R. Reducing antibiotic use for acute bronchitis in primary care: Blinded, randomised conrolled trial of patient information leaflet. Br Med J 2002;324:91-4.
299. Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. Br J Med Econ 1995;8:11-25.
300. Wool C, Cerutti R, Garbagna N, Grossi E. A cost-effectiveness study of four different antibiotics in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Br J Med Econ 1996;10:159-68.
301. van Barlingen HJJ, Nuijten MJC, Volmer T. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbation of chronic bronchitis in Germany. J Med Econ 1998;1:210-8.
302. Pechere JC, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:19-24.
303. LeLorier J, Derderian F. Effect of listing ciprofloxacin in provincial formularies in hospitalizations for bronchitis and pyelonephritis. Can J Clin Pharmacol 1998;5:133-7.
304. Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can Respir J 2000;7:466-71.
305. Allegra L, Blasi F, deBernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: A re-evaluation of previously published data of a placebo controlled randomized study. Pulm Pharmacol Ther 2001;14:149-55.
306. Torrance G, Walker V, Grossman R. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520.
307. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med 1991;91(6A):87S-92S.
308. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin versus clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:730-8.
309. Wilson R, Schentag J, Ball P, Mandell L, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-52.
310. Wilson R, Jones P, Schaberg T, et al. A clinical and outcomes assessment of the management of acute exacerbations of chronic bronchitis (AECB): The Mosaic Study. 12th ERS Annual Congress Stockholm, Sweden, 2002.
311. Ho P, Tse W, Tsang K, Ng T, Cheng V, Chan R. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study. Clin Infect Dis 2001;32:701-7.
312. Canadian Lung Association, Health Canada, Statistics Canada, Canadian Institute for Health Information. Tobacco use. Respiratory disease in Canada. Ottawa, Canada: Health Canada, 2001:11-7.
313. 1: The Lung Health Study. JAMA 1994;272:1497-505.
314. Higgins M, Enright P, Kronmal R, Schenker M, Anton-Culver H, Lyles M. Smoking and lung function in elderly men and women. The cardiovascular health study. JAMA 1993;269:2741-8.
315. Postma D, Sluiter H. Prognosis of chronic obstructive pulmonary disease: the Dutch experience. Am Rev Respir Dis 1989;140:S100-5.
316. Wynder E, Kaufman P, Lesser R. A short-term follow-up study on ex-cigarete smokers. With special emphasis on persistent cough and weight gain. Am Rev Respir Dis 1967;96:645-55.
317. Rutgers S, Postma D, ten Hacken N, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8.
318. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995;152:1262-7.
319. Fiore M. US public health service clinical practice guidelines: Treating tobacco use and dependence. Respir Care 2000;45:1200-62.
320. Jorenby D, Leischow S, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
321. Carilli A, Gohd R, Gordon W. A virologic study of chronic bronchitis. N Engl J Med 1964;270:123-7.
322. Lamy M, Ponthier-Simon F, Debacker-Williame E. Respiratory viral infections in hospital patients with chronic bronchitis. Chest 1973;63:336-41.
323. Walsh E, Falsey A, Hennessey P. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med 1999;160:791-5.
324. Nichol K, Margolis K, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
325. Nichol K, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalizations and mortality among elderly patients with chronic lung disease. Ann Intern Med 1999;130:397-403.
326. Fine M, Smith M, Carson C, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
327. Hutchison B, Oxman A, Shannon H, Lloyd S. Clinical effectivenes of pneumococcal vaccines: Meta-analysis. Can Fam Physician 1999;45:2381-93.
328. Nichol K, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly patients with chronic lung disease. Arch Intern Med 1999;159:2437-42.
329. Butler J, Breiman R, Campbell J, Lipman H, Broome C, Facklam R. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993;270:1826-31.
330. Centre for disease control and prevention. Prevention of pneumococcal disease. 46 (RR-8), 1-24 1997. MMWR Morb Mortal Wkly Rep. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm, Rep. 1997 Apr 4;46(RR-8):1-24.
331. Clancy R, Cripps A, Gebski V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. Med J Aust 1990;152:413-6.
332. Foxwell A, Cripps A. Haemophilus influenzae oral vaccination against accute bronchitis. Cochrane Database Syst S Rev 2000;(2): CD001958.
333. Orcel B, Delclaux B, Baud M, Derenne J. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionlized patients with chronic bronchitis. Eur Respir J 1994;7:446-52.
334. Collett J, Shapiro S, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease.The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997;156:1719-24.
335. Collett J, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Respir J 2001;8:27-33.
336. Thompson A, Mueller M, Heires A, et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992;146:389-95.
337. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflamation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5.
338. Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids in stable COPD patients: Do they have effects on cells and molecular mediators of airway inflammation. Chest 2000;117:1633-7.
339. Cox G, Whitehead L, Dolovich M, Jordanna M, Gauldie J, Newhouse M. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. Chest 1999;115:1271-7.
340. Culpitt SV Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
341. Loppow D, Schleiss MB, Kanniess F, Taube C, Jorres RA, Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:115-21.
342. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
343. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819-23.
344. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. Br Med J 2000;320:1297-303.
345. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive
346. Paggiaro, PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-80.
347. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2001;164:580-4.
348. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic air flow obstruction: Can corticosteroids slow down progression? Eur J Respir Dis 1985;67:56-64.
349. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic air flow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988;1:22-6.
350. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109:1156-62.
351. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43.
352. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-9.
353. Schols A, Wesseling G, Kester A, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001;17:337-42.
354. Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial. Am J Respir Crit Care Med 2000;162:174-8.
355. Dowling RB, Rayner CF, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997;155:327-36.
356. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998;11:86-90.
357. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
358. Vincken W, van Noord J, Greefhorst A, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
359. Casaburi R, Mahler D, Jones P, Wanner A, San Pedro G, ZuWallack R. A long-term evaulation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
360. Poole P, Black P. The effect of mucolytic agents on exacerbation frequency in chronic bronchitis. The Cochrane Library. Oxford: Update software, 1998.
361. Stey C, Steurer J, Bachmann S, Medici T, Tramer N. The effects of oral N-acetylcysteine in chronic bronchitis: A quantitative systemic review. Eur Respir J 2000;16:253-62.
362. Poole PJ, Black PN. Oral mucolytic drugs for exacerbating of chronic obstructive pulmonary disease: A systemic review. Br Med J 2001;322:1271-4.
363. Grandjean E, Berthet P, Ruffman R, Lenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol Res 2000;42:39-50.
364. Vecchiarelli A, Dottorini M, Pietrella D, et al. Macrophage activation by N-acetyl-cysteine in COPD patients. Chest 1994;105:806-11.
365. Venger P, Pederson B, Hahansson L, Hallgren R, Lindblad G, Dahl R. Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. Am J Respir Crit Care Med 1996;153:312-6.
366. Ruben F. Prophylactic treatment of chronic bronchitis. Sem Respir Infec 1988;3:72-80.
367. Liippo K, Pelliniemi T-T, Lehto H. Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary disease. Acta Med Scand 1987;21:455-9.
368. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on the trials of chemotherapy in early chronic bronchitis. Br Med J 1966;5499:317-22
369. Francis R, Spicer C. Chemotherapy in chronic bronchitis: Influence of daily penicillin and tetracycline on exacerbations and their cost. Br Med J 1960;1:297-303.
370. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest 2001;120:730-3.
371. Albert R, Martin T, Lewis S. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980;92:753-8.
372. Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46:1295-301.